Tom Hedman, Ph.D., Founder and Chief Science Officer of Intralink-Spine, Inc. “Our outstanding early data also indicates that 85% of these patients had good or excellent clinical results from the 2-week through 2-year post-treatment time-points."
The certification process included an on-site audit of ILS’s newly constructed GMP manufacturing facility in Lexington, KY.
The company reports the Réjuve treatment has the potential to fill the gap between non-operative treatments and surgery.
Intralink-Spine, Inc. Announces Initiation of Clinical Trials in Australia for their Patented Device Réjuve™
3/5/19: According to Hawkins, “We believe the Réjuve medical device, which structurally reinforces the native intervertebral disc itself, is going to be a better treatment option for many patients with low back pain.
3/27/18: Company has restructured for growth and to better position themselves for a successful CE submission.
“We’ve demonstrated the safety of this device, and it has performed as expected. The dramatic pain reduction in these patients correlated with some objective measures: there was an average increase in lumbar range of motion of 9...